drugset / Trial / NCT00051675
Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, immunogenicity, and tolerability of a monoclonal antibody administered subcutaneously in the treatment of advanced cancers of the ovary, breast, lung, prostate, colon or rectum that are either refractory to standard therapies or for which therapies that may potentially be of major benefit do not exist.
Timeline
- Start
- 2002-07
- Primary completion
- —
- Completion
- 2003-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ING-1(heMAb) | Monoclonal antibody | — | Subcutaneous |